ATB Cormark Capital Markets Issues Pessimistic Forecast for Tilray Brands (NASDAQ:TLRY) Stock Price

Tilray Brands (NASDAQ:TLRY) had its price objective lowered by analysts at ATB Cormark Capital Markets from $9.50 to $9.00 in a research note issued to investors on Thursday,BayStreet.CA reports. The firm presently has a “sector perform” rating on the stock. ATB Cormark Capital Markets’ price objective would suggest a potential upside of 37.40% from the company’s current price.

TLRY has been the topic of a number of other research reports. Canaccord Genuity Group initiated coverage on shares of Tilray Brands in a research report on Tuesday, January 27th. They issued a “hold” rating on the stock. Roth Mkm raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $11.20.

Tilray Brands Price Performance

Shares of NASDAQ TLRY opened at $6.55 on Thursday. The company has a 50 day simple moving average of $7.27 and a 200 day simple moving average of $10.19. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.72. Tilray Brands has a 1 year low of $3.51 and a 1 year high of $23.20. The firm has a market cap of $763.14 million, a PE ratio of -0.48 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). The business had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same period in the previous year, the firm earned ($0.87) earnings per share. On average, research analysts forecast that Tilray Brands will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC bought a new stake in shares of Tilray Brands in the fourth quarter valued at approximately $38,000. Engineers Gate Manager LP bought a new stake in shares of Tilray Brands during the fourth quarter valued at about $126,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Tilray Brands in the third quarter worth about $25,000. Silverlake Wealth Management LLC purchased a new stake in shares of Tilray Brands in the third quarter worth about $25,000. Finally, Unified Investment Management bought a new position in shares of Tilray Brands in the third quarter valued at approximately $26,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth/MKM upgraded TLRY to Buy (new $10 price target), citing the Q3 results as a catalyst for improved sentiment—this upgrade supports near-term buying interest. Roth upgrade coverage
• Positive Sentiment: Jefferies reiterated a Buy and kept a $24 price target, pointing to strong cannabis sales and better medium‑term visibility; a high PT from a major shop increases upside narratives for investors. Jefferies note
• Positive Sentiment: Regulatory tailwind: reports that the FDA won’t enforce some CBD regulations spurred sector buying, lifting Tilray alongside peers and improving the outlook for CBD revenue. FDA/CBD coverage
• Positive Sentiment: Product/brand news — Tilray Beverages’ Shock Top launched a high‑ABV beer (High Voltage), a growth/innovation signal for the beverages segment that can help top-line recovery over time. Shock Top launch
• Neutral Sentiment: Analyst/deep-dive pieces see TLRY as improving but still mixed: commentary highlights revenue growth, international cannabis up ~73% in Q3, and narrowing losses but cautions on margins, cash flow and M&A execution. This frames TLRY as a recovery story with execution risk. Seeking Alpha analysis
• Neutral Sentiment: Zacks and other commentary call Q3 mixed—revs beat slightly and losses narrowed, but beverage weakness and margin pressure temper bullish cases. Zacks piece
• Negative Sentiment: Earnings miss: TLRY reported Q3 EPS of -$0.24 vs. consensus -$0.14 (revenue ~$206.7M vs. est. ~$201.4M). The EPS shortfall on the call raised concerns about margins and profitability despite top-line improvements. MSN earnings transcript InsiderMonkey transcript
• Negative Sentiment: ATB Cormark trimmed its price target to $9.00 and moved to sector perform, signaling more conservative near‑term expectations and adding selling pressure from cautious analysts. ATB Cormark note

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.